DNABEATS: Customised DNA-based nanocarriers to boost heart healing.


Myocardial infarction and its evolution towards heart failure is a leading cause of death in Europe. No curative treatment aside heart transplantation has been accomplished so far. DNABEATS aims to bring advanced materials to regenerate injured myocardium. Cutting-edge DNA nanotechnology is exploited for the fabrication of fully customised biocompatible DNA-based nanocarriers (DNCs) to achieve the cardio-targeted and efficient delivery of a regenerative microRNA.

The therapeutic efficacy of DNCs will be assessed in human-derived cardiac cells, a ground-breaking aspect, that together with an exhaustive in vitro and in vivo biocompatibility investigation, will facilitate their future clinical application and industrial transfer. DNABEATS entails thus benefits for multiple stakeholders from industry to patients and clinicians. Sustainability is also present in the project and different dissemination and exploitation actions are planned to maximise the socio-economic impacts.

Objetivos y Resultados

DNABEATS proposes innovative nanocarriers customised to cardio-direct the delivery of heart regenerative miR molecules using an approach with high translational value. Four aims have been set to accomplish the general scientific goal:

● Developing multifunctional DNCs loaded with cardio-therapeutic miRs.
● Characterising DNCs stability under biological conditions.
● Demonstrating DNCs selectivity and therapeutic efficacy.
● Assessing DNCs biocompatibility in vitro and in animal models.

IP IIS Aragón

Laura Ordovás

Organismo Financiador

Subvención económica concedida dentro de las convocatorias competitivas internacionales de “Proyectos de Colaboración Internacional (PCI)” de la Agencia Estatal de Investigación (AEI 2021 – 2023) al proyecto “CUSTOMISED DNA-BASED NANOCARRIERS TO BOOST HEART HEALING” (PCI2023-143438), perteneciente al proyecto consorciado “Customised DNA-based nanocarriers to boost heart healing – DNABeats” de la Acción Conjunta Internacional M-ERA.NET 3 cofund 2022.

El proyecto PCI2023-143438 está financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea.

Presupuesto total del Proyecto: 866.862 €
Presupuesto IIS Aragón: 123.420 €


Universidad de Zaragoza (España)


- University of Tartu (Estonia)
- Fundación Instituto de Investigación Sanitaria Aragón (España)
- Vilnius University (Lituania)
- Jagiellonian University (Polonia)


01/09/2023 – 31/08/2026 (36 meses)

Página web